Anna MariaVStornioloMD

Oncology • Indianapolis, IN

Physician

Join to view full profile

Dr. Storniolo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Storniolo's full profile

Already have an account?

Office
535 Barnhill Dr
# ROUTE473
Indianapolis, IN 46202
Phone+1 317-278-7576

Fax+1 317-948-6796

Education & Training

University of RochesterFellowship, Hematology and Medical Oncology, 1985 - 1987
University of RochesterFellowship, Hematology and Medical Oncology, 1984 - 1985
University of RochesterResidency, Internal Medicine, 1981 - 1982
Stanford University School of MedicineClass of 1981

Certifications & Licensure

CA State Medical License 1987 - Present
IN State Medical License 1994 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Aromatase Inhibitor Clinical Trial Start of enrollment: 2005 Jan 01
Unknown status
Collection of Tissue Samples for Cancer Research Start of enrollment: 2006 Jul 06
Recruiting
Roles: Contact
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer Start of enrollment: 2018 Jun 21
Active, not recruiting
Phase 2
Roles: Contact
Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease Start of enrollment: 2017 Sep 02
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer Start of enrollment: 2021 Jun 01
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

86 citations
A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin.
Gary K. Schwartz, David C Ward, Leonard B. Saltz, Ephraim S. Casper, Tara Spiess
Clinical Cancer Research. 1997-04-01
8 citations
Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer is driven by CpGs associated with polycomb-related genes.
Mariya Rozenblit, Erin Hofstatter, Zuyun Liu, Tess O'Meara, Anna Maria Storniolo
Clinical Epigenetics. 2022-02-24
76 citations
Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study.
Kala Visvanathan, Maryjo S. Fackler, Zhe Zhang, Zoila A. Lopez-Bujanda, Stacie Jeter
Journal of Clinical Oncology. 2017-03-01

Other Languages

Italian